In addition to providing patients first-class treatment, our team is dedicated to learning more about ocular melanoma and potential new therapies through clinical research. Areas of focus in our research include:
- Understanding the mutations that drive ocular melanoma and identifying therapies that target these mutations
- Identifying risk factors for metastases and intervening earlier in treatment to prevent spread
- Developing the next generation of melanoma therapeutics and translating them to innovative investigator-initiated clinical trials
- Evaluating the cancer's resistance to immunotherapy
Featured Clinical Trial
A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects with Metastatic Melanoma
Trial Description: This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic ocular (uveal) melanoma and NRAS-mutant metastatic melanoma.